Phase II Clinical Trials of Novel Therapies for Lung Diseases (UM1)

The summary for the Phase II Clinical Trials of Novel Therapies for Lung Diseases (UM1) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Phase II Clinical Trials of Novel Therapies for Lung Diseases (UM1)
	CFDA Number:	93.838
	CFDA Description:	Lung Diseases Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-HL-12-022
	Document Type:	Grants Notice
	Funding Instrument Type:	Cooperative Agreement
	Posted Date:	Mar 17, 2011
	Creation Date:	Mar 17, 2011
	Original Closing Date for Applications:	Sep 13, 2012
	Current Closing Date for Applications:	Sep 13, 2012
	Archive Date:	Oct 14, 2012
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Foreign (non-U.S.) components of U.S. Organizations are not allowed.
Grant Description: This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute, National Institutes of Health, solicits grant applications from institutions/organizations to conduct proof-of- concept Phase II clinical trials that test a novel intervention for a lung disease or a cardiopulmonary disorder from sleep that has the potential to significantly change clinical management. In addition, each application must include at least one basic research ancillary study tightly related to the clinical question.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-hl-12-022.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Short-Term Institutional Training Grant for Clinician Scientists in Pediatric Respiratory, Sleep and...; • Development and Testing of a Case Finding Methodology in COPD (R01); • Maximizing the Scientific Value of the NHLBI Biologic Specimen Repository: Scientific Opportunities ...; • Genomic Research in AAT-Deficiency and Sarcoidosis study (GRADS) Cooperative Research Project Grant:...; • Genomic Research in AAT-Deficiency and Sarcoidosis study (GRADS) Cooperative Research Project Grant:...; • PATHOGENESIS OF SARS LUNG DISEASE: IN VITRO STUDIES AND ANIMAL MODELS; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01); • ASTHMA CLINICAL RESEARCH NETWORK; • COPD CLINICAL RESEARCH NETWORK